AZD3470

Overview

AZD3470 is an orally active MTA-cooperative PRMT5 inhibitor, selective for MTAP-deficient tumors. AZD3470 induces cell cycle G 2 /M phase alterations, DNA damage, apoptosis , and symmetric dimethylarginine reduction. AZD3470 alters alternative splicing, increases skipped exon events in DNA repair and cell cycle pathways, and inhibits cancer cell proliferation and tumor growth. AZD3470 can be used for the research of non-small cell lung cancer and MTAP -deleted solid tumors.

Application

Products | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-158143
• CAS No.: 2918814-97-6
• Molecular Formula: C23H19F2N5O2
• Molecular Weight: 435.43
• Purity: 99.74%
• Storage: 4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (5.74 mM); Clear solution
• Availability: In-stock

Source

Original product source